Drug Immunology

Spevigo

Payments companies reported to CMS as associated with Spevigo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$3.1Massociated payments (2023-2025)

9,122clinicians with associated payments

4companies reporting

By year

2023 $1.1M

2024 $1.3M

2025 $803K

Payments reported as associated with Spevigo, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Dermatology $2.0M

Physician Assistant $225K

Mohs-Micrographic Surgery $148K

Anesthesiologist Assistant $112K

Clinical & Laboratory Dermatological Immunology $106K

Family $78K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Spevigo

These are the largest totals companies reported as associated with Spevigo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Dario Kivelevitch	Lancaster, TX	Dermatology	$117,219.79
Stephen Feldman	Decatur, GA	Anesthesiologist Assistant	$112,259.50
Aaron Farberg	Rockwall, TX	Mohs-Micrographic Surgery	$100,650.10
Stanislav Tolkachjov	Lewisville, TX	Dermatology	$97,238.10
Cory Rubin	Waterford, MI	Clinical & Laboratory Dermatological Immunology	$80,409.55
Jason Hawkes	Portland, OR	Dermatology	$75,717.53
Brad Glick	Margate, FL	Dermatology	$71,527.10
George Drew	Marion, OH	Dermatology	$69,469.04
Karl Saardi	Washington, DC	Dermatology	$66,441.20
Scott Worswick	Los Angeles, CA	Dermatology	$64,725.02

Prescribed Spevigo?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.